Concomitant <i>TP53</i> mutations with response to crizotinib treatment in patients with <i>ALK</i>‐rearranged non‐small‐cell lung cancer

Abstract

TP53 mutations, especially nondisruptive mutations, negatively affected the response to crizotinib and correlated with shorter PFS in ALK-rearranged NSCLC patients.